Stockscreener 앱 받기
4.2307
7.29%
-0.3493
전일 마감가:
$4.58
열려 있는:
$4.58
하루 거래량:
150.23K
Relative Volume:
0.62
시가총액:
$130.19M
수익:
$71.61M
순이익/손실:
$-48.59M
주가수익비율:
-2.4162
EPS:
-1.751
순현금흐름:
$-32.88M
1주 성능:
+1.22%
1개월 성능:
-4.79%
6개월 성능:
+8.60%
1년 성능:
-32.38%
1일 변동 폭
$4.23
$4.67
1주일 범위
$4.10
$4.85
52주 변동 폭
$3.22
$7.12
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
4.23 | 140.96M | 71.61M | -48.59M | -32.88M | -1.751 |
ABT
Abbott Laboratories
|
86.64 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
311.87 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.72 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.61 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.32 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Northland Capital | Outperform |
| 2025-11-20 | 업그레이드 | BTIG Research | Sell → Neutral |
| 2025-08-08 | 다운그레이드 | BTIG Research | Neutral → Sell |
| 2024-12-24 | 개시 | D. Boral Capital | Buy |
| 2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-02 | 개시 | Piper Sandler | Overweight |
| 2020-08-27 | 개시 | BofA Securities | Buy |
| 2020-04-21 | 개시 | Oppenheimer | Outperform |
| 2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
Avita Medical Stock Price Forecast. Should You Buy RCEL? - StockInvest.us
Avita Medical Q1 earnings call highlights - MSN
Morgans says these ASX shares could rise 12% to 20% - MSN
Insider Buying: David O'Toole Acquires Shares of AVITA Medical I - GuruFocus
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market buy - Stock Titan
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market purchase - Stock Titan
AVITA Medical to Host Investor Webinar Briefing - Investing News Network
AVITA Medical to Host Investor Webinar Briefing | Associated Press | syndication news - Enidnews.com
Two AVITA Medical investor Q&As with CEO Cary Vance on May 20–21 - Stock Titan
AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2026 Earnings Call Transcript - Insider Monkey
AVITA Medical Q1 2026 earnings preview - MSN
RCEL Upgraded by Lake Street -- Price Target Raised to $6.00 - GuruFocus
Avita Medical Raised to Buy From Hold by Lake Street - Moomoo
Avita Medical, Inc. Stock 12‑Month Price Target Raised to $6.99, Implies 60% Upside - TradingView
Avita (RCEL) Q1 2026 Earnings Call Transcript - The Globe and Mail
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $5.5 - Moomoo
AVITA Medical, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Avita reaffirms $80M-$85M 2026 revenue guidance as RECELL reimbursement normalizes and Cohealyx data targets faster graft readiness - MSN
Lake Street upgrades AVITA Medical (RCEL) - MSN
RCEL Reports Q1 Revenue Below Expectations - GuruFocus
RCEL Revenue Forecast for FY26 Indicates Strong Growth Potential - GuruFocus
Is AVITA Medical (RCEL) a Value Trap Despite Q1 2026 Revenue Bea - GuruFocus
AVITA Medical Inc (AVHHL) Q1 2026 Earnings Call Highlights: Reve - GuruFocus
Avita Medical Posts Narrower Q1 Loss, Higher Revenue; Reaffirms Full-Year 2026 Outlook - Moomoo
AVITA Medical's (ASX:AVH) First Quarter 2026 Results and Strategic Reset Explained - Kalkine
Avita Medical Q1 Earnings Call Highlights - MarketBeat
AVITA Medical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RCEL: Revenue rose 4% year-over-year to $19.3M, with improved margins and reaffirmed guidance - TradingView
Avita Medical earnings missed by $0.06, revenue topped estimates - Investing.com Canada
AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
AVITA Medical Reports First Quarter 2026 Financial Results - Investing News Network
Avita Medical stock (US0301011039): Q1 2026 results and revenue details - AD HOC NEWS
RCEL: Q1 2026 delivered revenue growth, improved margins, and strong clinical momentum for new products - TradingView
Q1 2026 AVITA Medical Inc Earnings Call Transcript - GuruFocus
AVITA Medical (RCEL) posts Q1 2026 loss, adds new credit line and BARDA deal - Stock Titan
AVITA Medical (RCEL) Q1 2026 revenue rises 4% as losses narrow and 2026 outlook held - Stock Titan
AVITA Medical, Inc. Reaffirms Earnings Guidance for the Full Year 2026 - marketscreener.com
AVITA Medical Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Avita Medical stock (US0301011039): Shares surged 7.75% in July 2025 - AD HOC NEWS
TradingKey - TradingKey
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
AVITA Medical Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
RCEL Stock Price, Quote & Chart | AVITA MEDICAL INC (NASDAQ:RCEL) - ChartMill
Avita Medical (RCEL) Expected to Announce Earnings on Thursday - MarketBeat
AVITA Medical appoints Cary Vance as permanent CEO - MSN
AVITA Medical Appoints Cary Vance as Permanent CEO and Jan Stern Reed as Board Chair to Drive Growth in Acute Wound Care Solutions - Minichart
Avita Medical Names Cary Vance Permanent CEO, Reshapes Board - The Globe and Mail
Avita Medical (NASDAQ:RCEL) Stock Rating Lowered by Wall Street Zen - MarketBeat
AVITA Medical wins BARDA contract worth up to $25.5M - MSN
Cary Vance becomes AVITA Medical (NASDAQ: RCEL) CEO as Board elevates Jan Stern Reed to Chair - Stock Titan
Avita Medical Appoints CEO, Chair - Moomoo
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Avita Medical Inc 주식 (RCEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| O'Toole David D | CFO |
May 19 '26 |
Buy |
4.24 |
2,000 |
8,480 |
143,927 |
| O'Toole David D | CFO |
Feb 19 '26 |
Buy |
4.15 |
3,000 |
12,450 |
140,127 |
| McNamara Robert | Director |
Aug 28 '25 |
Buy |
4.50 |
10,000 |
45,000 |
86,771 |
| O'Toole David D | CFO |
Aug 26 '25 |
Buy |
4.52 |
2,000 |
9,040 |
31,657 |
| McNamara Robert | Director |
Aug 19 '25 |
Buy |
5.00 |
10,000 |
50,000 |
76,771 |
| O'Toole David D | CFO |
Aug 12 '25 |
Buy |
4.81 |
2,000 |
9,620 |
29,657 |
0.32%
0.17%
자본화:
|
볼륨(24시간):